Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT06858020
Recruiting Not applicable

NoPro - Norwegian Hernia Prophylaxis Study

NCT06858020 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2025-02-17
Last updated
2025-03-05

Condition(s) studied

Incisional Hernia After Midline LaparotomyQuality of Life (QOL)Burst AbdomenSurgical Site Infections

Investigational drug(s) / intervention(s)

Prophylactic polypropylene onlay mesh

Prophylactic polypropylene onlay mesh: The patients in the mesh group are closed with small bites technique and in addition receiving an onlay polypropylene mesh when closing the fascia in midline laparotomies.

Study summary

A multicenter randomized controlled trial comparing midline laparotomy closures using the small-bite suture technique alone to those using the small-bite suture technique with an additional onlay prophylactic polypropylene mesh. The primary endpoint is the incidence of incisional hernias in both groups after one year.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Surgery predominantly done my midline laparotomy * Age 18 years old or older * Written consent by patient/family * Midline laparotomy with delayed closure * No exclusion criteria Exclusion Criteria: * Age under 18 years * Pregnancy * Previous abdominal midline hernia mesh repair * Abdominal compartment syndrome * Linea alba closure not possible * Life expectancy under six months * Hernia in the midline with transverse diameter lager than 2 cm

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Innlandet Hospital Trust Hamar Norway Recruiting

More Sykehuset Innlandet HF trials in Norway

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06858020 on ClinicalTrials.gov ↗ ← All trials in Norway